Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis

Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis

Background: Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional...

Full description

Bibliographic Details
Main Authors: Bibie N Said, Scott K Heysell, Getnet Yimer, Rob E Aarnoutse, Gibson S Kibiki, Stellah Mpagama, Peter M Mbelele
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:International Journal of Mycobacteriology
Subjects:
mycobacterial activity
pharmacodynamic biomarkers
tuberculosis
tuberculosis drug activity
Online Access:http://www.ijmyco.org/article.asp?issn=2212-5531;year=2021;volume=10;issue=4;spage=457;epage=462;aulast=Said

Internet

http://www.ijmyco.org/article.asp?issn=2212-5531;year=2021;volume=10;issue=4;spage=457;epage=462;aulast=Said

Similar Items